Roche schizophrenia drug that failed PhIII gets a new life in rare disorder as OrbiMed leads $90M for startup
Until a few years ago, GlyT1, a glycine transporter, seemed like a promising target for an add-on therapy to treat negative symptoms of schizophrenia.
But scientists were thrusted back to the drawing board in 2014, when Roche reported that its GlyT1 inhibitor, bitopertin, had failed two Phase III trials. A few months later, they scrapped the program altogether.
The drug sat on the shelves for seven years. Then Disc Medicine came along.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.